Cutler Group’s Alaunos Therapeutics TCRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-27
Closed -$7K 5198
2022
Q3
$7K Buy
+27
New +$7.84K ﹤0.01% 3415
2022
Q1
Sell
-9
Closed -$1K 6023
2021
Q4
$1K Hold
9
﹤0.01% 5140
2021
Q3
$2K Buy
9
+2
+29% +$612 ﹤0.01% 5097
2021
Q2
$2K Buy
+7
New +$3.27K ﹤0.01% 5082
2019
Q1
Sell
-7
Closed -$1K 4731
2018
Q4
$1K Sell
7
-67
-91% -$26.5K ﹤0.01% 3713
2018
Q3
$33K Buy
74
+37
+100% +$15.9K ﹤0.01% 1891
2018
Q2
$16K Sell
37
-4
-10% -$2.54K ﹤0.01% 2350
2018
Q1
$24K Buy
41
+10
+32% +$6.23K ﹤0.01% 2158
2017
Q4
$19K Sell
31
-12
-28% -$8.62K ﹤0.01% 2612
2017
Q3
$39K Buy
43
+40
+1,333% +$35.5K ﹤0.01% 2478
2017
Q2
$3K Buy
+3
New +$2.94K ﹤0.01% 5308
2017
Q1
Sell
-152
Closed -$142K 7193
2016
Q4
$122K Buy
152
+100
+192% +$90.1K ﹤0.01% 1738
2016
Q3
$44K Buy
52
+8
+18% +$6.43K ﹤0.01% 2593
2016
Q2
$35K Sell
44
-27
-38% -$29.4K ﹤0.01% 2738
2016
Q1
$79K Sell
71
-394
-85% -$403K 0.01% 1848
2015
Q4
$579K Buy
+465
New +$769K 0.03% 551

Other funds holding TCRT

Cutler Group's TCRT Position: Q4 2022 in Review

Cutler Group sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 27 shares — an estimated $7K sold.

Cutler Group first reported a position in TCRT in Q4 2015 and held it in 16 quarters. The position peaked at $579K in Q4 2015. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • Cutler Group reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 27 Alaunos Therapeutics shares in Q4 2022, an estimated $7K.
  • Cutler Group first reported a position in Alaunos Therapeutics in Q4 2015 and held it in 16 quarters.
  • Cutler Group's Alaunos Therapeutics position peaked at $579K in Q4 2015.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.